Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oxx in connection with the establishment of Oxx II
Mandate

Vinge has advised Oxx in connection with the establishment of Oxx II

December 07, 2023 Private Funds

Oxx closes its second fund generation with USD 190 million in commitments from an international investor base, and thereby increases the fund size by 40% since its latest fund announcement.

Oxx was founded in 2017 and primarily invests in European companies within the B2B SaaS scale-up space.
Vinge’s team primarily consisted of Mattias Schömer, Jesper Ottergren, Viveka Classon, Martin Cronsioe, Semir Omerbasic and Viktoria Wnuk.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026